Anzahl der Publikationen: 5
Zeitschriftenartikel
Boukovala, Myrto; Modest, Dominik Paul; Ricard, Ingrid; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Peveling Genannt Reddemann, C.; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Schuch, Gunter ORCID: https://orcid.org/0000-0001-7503-457X; Schwaner, Ingo ORCID: https://orcid.org/0000-0001-8865-7282; Heinrich, Kathrin ORCID: https://orcid.org/0000-0003-3580-2313; Neumann, Jens; Jung, Andreas; Held, Swantje ORCID: https://orcid.org/0000-0002-1344-9056; Stintzing, Sebastian ORCID: https://orcid.org/0000-0002-3297-5801; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Michl, Marlies ORCID: https://orcid.org/0000-0002-4198-3627
(2024):
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
In: ESMO Open, Bd. 9, Nr. 5, 103374
[PDF, 725kB]
Stahler, Arndt; Modest, Dominik P.; Fischer von Weikersthal, Ludwig; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Kurreck, Annika; Heinrich, Kathrin; Giessen-Jung, Clemens; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Stintzing, Sebastian und Heinemann, Volker
(2022):
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
In: European Journal of Cancer, Bd. 173: S. 194-203
Stahler, Arndt; Heinemann, Volker; Schuster, Veronika; Heinrich, Kathrin; Kurreck, Annika; Giessen-Jung, Clemens; Weikersthal, Ludwig Fischer von; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Kumbrink, Jorg; Stintzing, Sebastian und Modest, Dominik P.
(2021):
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
In: European Journal of Cancer, Bd. 157: S. 71-80
Kurreck, Annika; Heinemann, Volker; Fischer von Weikersthal, Ludwig; Decker, Thomas; Kaiser, Florian; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Graeven, Ullrich; Schwaner, Ingo; Stahler, Arndt; Heinrich, Kathrin; Jung, Andreas; Held, Swantje; von Einem, Jobst C.; Stintzing, Sebastian; Giessen-Jung, Clemens und Modest, Dominik P.
(2020):
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
In: European Journal of Cancer, Bd. 137: S. 81-92
Modest, Dominik Paul; Fischer von Weikersthal, Ludwig; Decker, Thomas; Vehling-Kaiser, Ursula; Uhlig, Jens; Schenk, Michael; Freiberg-Richter, Jens; Peuser, Bettina; Denzlinger, Claudio; Reddemann, Christina Peveling Genannt; Graeven, Ullrich; Schuch, Gunter; Schwaner, Ingo; Stahler, Arndt; Jung, Andreas; Kirchner, Thomas; Held, Swantje; Stintzing, Sebastian; Giessen-Jung, Clemens und Heinemann, Volker
(2019):
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110).
In: Journal of Clinical Oncology, Bd. 37, Nr. 1
Diese Liste wurde am
Sat Nov 16 20:53:09 2024 CET
erstellt.